Industry is already pessimistic that an electronic, interoperable system to trace drug products at the package-level will be in place by in the US by 2023, and disagreements among trade partners could make achieving that reality even more difficult than it already is.
At the first of three US FDA public meetings on the Drug Supply Chain Security Act (DSCSA) – which lays...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?